Drugs /

saracatinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
saracatinib
NCI Definition [1]:
An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.

Clinical Trials

View Clinical Trials for saracatinib

Saracatinib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating saracatinib, 1 is phase 1/phase 2 (0 open).

ER Expression, ER Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for saracatinib clinical trials.

Breast carcinoma is the most common disease being investigated in saracatinib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Saracatinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating saracatinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
azd0530, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)quinazolin-4-amine, 4-quinazolinamine, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1- piperazinyl)ethoxy)-5-((tetrahydro-2h-pyran-4-yl)oxy)-, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-((oxan-4-yl)oxy)quinazolin-4-amine, azd-0530, 4-quinazolinamine, n-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2h-pyran-4-yl)oxy]-, azd 0530, 4-quinazolinamine, n-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1- piperazinyl)ethoxy]-5-[(tetrahydro-2h-pyran-4-yl)oxy]-, saracatinib, 379231-04-6, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1-piperazinyl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)-4-quinazolinamine, src kinase inhibitor azd0530, n-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(tetrahydro- 2h-pyran-4-yl)oxy]quinazolin-4-amine
Drug Categories [2]:
SRC inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
ABL1, ABL2, SRC
NCIT ID [1]:
C48378

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.